Steroid-Free hope? early trial of ruxolitinib for young GVHD patients ends prematurely
NCT ID NCT06695507
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested whether the drug ruxolitinib could be used as the first treatment for chronic graft-versus-host disease (cGVHD) in children and young adults, instead of the usual high-dose steroids. The goal was to see if it could control the disease while avoiding steroid side effects. However, the study was terminated early and only enrolled one participant, so no meaningful conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ruxolitinib
- What this could lead to
- If successful, this approach could reduce the need for high-dose steroids in young patients with chronic GVHD, potentially lowering side effects while still controlling the disease.
- What could go wrong
- This was a very small, early-phase pilot study that was terminated after enrolling only 1 participant. The results are not generalizable, and the effectiveness of upfront ruxolitinib remains unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can meditation tame the Long-Term side effects of a stem cell transplant?
- Could a liquid form of a Graft-Versus-Host disease drug be as effective as the pill?
- Scientists map immune battlefield in chronic GVHD tissue
- Could a rheumatoid arthritis drug tame chronic GVHD and cut steroid use?
- Could an arthritis drug tame a tough transplant complication?
- New hope for teens with chronic Graft-Versus-Host disease: belumosudil under study